DORADO, PR / ACCESS Newswire / January 29, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that revenues for the year ended October 31, 2025 were approximately $9.0 million, a decrease of approximately $0.5 million when compared t ...

Core Viewpoint - Salesforce, Inc. has officially agreed to acquire Informatica Inc. for approximately $8 billion in equity value, net of Salesforce's current investment in Informatica [1] Group 1: Acquisition Details - Holders of Informatica's Class A and Class B-1 common stock will receive $25 in cash per share under the terms of the agreement [1] - Upon close, Salesforce plans to rapidly integrate Informatica's technology stack, including data integration, quality, governance, and unified metadata for Agentforce, along with a single data pipeline with MDM on Data Cloud [2] Group 2: Market Reaction - Informatica shares gained 0.5% to trade at $24.04 following the announcement [2] - Analysts have adjusted their price targets for Informatica post-announcement, with RBC Capital raising the target from $22 to $25 and Wells Fargo raising it from $19 to $25 [7]